2bPrecise, an EHR-agnostic, cloud-based precision medicine platform, today announced it is collaborating with PierianDx, Inc., the leading clinical genomics knowledge base company, to offer a comprehensive precision medicine solution. The combined solution brings together genomic and clinical data to help providers make more informed care decisions for their patients. This unique technology enables clinicians to concentrate on the most important information to determine what is best for each patient.
Precision medicine should be applied to cancer patients of any stage now through holistic clinical, genomic, and knowledgebase integration, while supporting the most complex patients as part of a Molecular Tumor Board review. With this forward-looking collaboration, 2bPrecise, an Allscripts company, would bring evidence-based knowledge from PierianDx’s Clinical Genomics WorkSpace™ (CGW) platform, the industry’s leading integrated workspace for clinical genomic analytics, classification, interpretation and reporting, directly to the point of care.
“We believe the power of precision medicine can best be achieved by combining a patient’s clinical data with genomic results at the point of care,” said Assaf Halevy, founder and CEO of 2bPrecise. “To that end,” he adds, “the companies’ collaborative effort will not simply repurpose clinical and genomic data on the desktop, but also provide the only solution that integrates a patient’s next generation sequencing (NGS) lab results from commercial and internal labs with relevant and critical clinical information. It then facilitates interpretation and clinical action using a comprehensive knowledge base comprised of scientific and evidence-based content, including previous patients’ outcomes.”